...
首页> 外文期刊>Journal of Medicinal Chemistry >2R,1'S,2'R,3'S)-2-(2'-Carboxy-3'-phenylcyclopropyl)glycine (PCCG-13), the first potent and selective competitive antagonist of phospholipase D-coupled metabotropic glutamate receptors: asymmetric synthesis and preliminary biological properties.
【24h】

2R,1'S,2'R,3'S)-2-(2'-Carboxy-3'-phenylcyclopropyl)glycine (PCCG-13), the first potent and selective competitive antagonist of phospholipase D-coupled metabotropic glutamate receptors: asymmetric synthesis and preliminary biological properties.

机译:2R,1'S,2'R,3'S)-2-(2'-羧基-3'-苯基环丙基)甘氨酸(PCCG-13),磷脂酶D偶联的代谢型谷氨酸受体的第一个有效的选择性竞争性拮抗剂:不对称合成和初步生物学特性。

获取原文
获取原文并翻译 | 示例
           

摘要

The asymmetric synthesis of (2R,1'S,2'R, 3'S)-2-(2'-carboxy-3'-phenylcyclopropyl)glycine (PCCG-13), a trisubstituted carboxycyclopropylglycine endowed with unusual stereochemical features, is described. Preliminary biological evaluation demonstrates PCCG-13 as a very potent and selective competitive antagonist for the novel class of metabotropic glutamate (mGlu) receptors coupled to the activity of phospholipase D (PLD). PCCG-13 is therefore a useful tool for the exploration of the physiopathological role of this novel class of receptors.
机译:描述了不对称合成的(2R,1'S,2'R,3'S)-2-(2'-羧基-3'-苯基环丙基)甘氨酸(PCCG-13),一种具有不同立体化学特征的三取代羧基环丙基甘氨酸。初步生物学评估表明,PCCG-13是一种新型的代谢型谷氨酸(mGlu)受体,与磷脂酶D(PLD)的活性非常有效且具有选择性竞争性拮抗剂。因此,PCCG-13是探索这种新型受体的生理病理作用的有用工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号